Subscribe To
ARCT / Raymond James analyst doesn't expect Arcturus' COVID-19 vaccine to be authorized in the U.S.
ARCT News
By Seeking Alpha
September 7, 2023
Arcturus: Interim Readout Of Rare Disease Data In Coming Months
Results from phase 2 study using ARCT-810 for the treatment of patients with Ornithine-Transcarbamylase [OTC] deficiency are expected in the coming mo more_horizontal
By Business Wire
August 17, 2023
Arcturus Therapeutics to Attend Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global l more_horizontal
By Zacks Investment Research
August 10, 2023
New Strong Sell Stocks for August 10th
ARCT, AVY and ASB have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2023. more_horizontal
By The Motley Fool
August 8, 2023
Why Shares of Arcturus Therapeutics Dropped on Tuesday
Arcturus Therapeutics has several collaboration agreements. The company is a clinical-stage biotech. more_horizontal
By Zacks Investment Research
August 7, 2023
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.98 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of more_horizontal
By InvestorPlace
July 28, 2023
3 Biotech Stocks to Buy Before the Breakout
During this Q3 of 2023, there have been many changes to U.S. healthcare at different levels. At the state level, there were changes to gender-affirmin more_horizontal
By Zacks Investment Research
July 17, 2023
Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains?
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings esti more_horizontal
By Seeking Alpha
June 26, 2023
Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race
Arcturus Therapeutics is developing mRNA medicines and vaccines for infectious diseases and rare disorders, with a focus on their ARCT-810 candidate f more_horizontal